De-Extinction as Trojan Horse for B2B and B2G Technology

This conversation with Ben Lamm, CEO of Colossal, reveals a compelling business strategy that transcends the sensationalism of de-extinction. While the public imagination is captured by the prospect of woolly mammoths, the true financial and strategic advantage lies in the underlying technological infrastructure Lamm is building. The non-obvious implication is that the pursuit of "cool" science is a Trojan horse for developing immensely valuable B2B and B2G (Business-to-Government) solutions in areas like drug discovery, conservation, and even national security. This insight is crucial for investors, technologists, and policymakers who are looking for sustainable, high-impact ventures that leverage cutting-edge science beyond consumer fads. It offers a blueprint for how ambitious, science-driven companies can create enduring value by focusing on foundational technologies with broad applicability.

The "Cool" as a Catalyst for Deep Technology

The public narrative around Colossal is, understandably, dominated by the reanimation of extinct species. Woolly mammoths, dodos, and dire wolves capture headlines and spark imaginations, a deliberate strategy, as Lamm explains, to compete for attention in a crowded digital landscape. However, this focus on the spectacular serves a deeper purpose: it acts as a powerful engine for developing and validating complex, multi-faceted technological systems. Lamm articulates this by framing the company's core mission not just as de-extinction, but as building an "end-to-end systems model" capable of complex genetic engineering.

This systems approach is where the true, less obvious value resides. The technologies required to engineer a woolly mammoth--advanced genome editing, computational biology, and sophisticated data analysis--are precisely the same tools needed for critical applications in human health, agriculture, and environmental conservation. Lamm highlights how these capabilities are being spun out into separate, highly valued companies: Colossal's Health division for drug discovery, a computational biology platform, and a company focused on plastic degradation. The profitability, he suggests, is "ludicrous" not from selling mammoth tickets, but from licensing these foundational technologies.

"The technologies that we're developing do two things right one the end to end systems model that allows you to make woolly mammoths can also directly be applied to making drought resistant animals or disease resistant plants or microbes that eat plastic so the same engine because it's a systems model that you have to build to create this allows you to build other things."

This strategic layering--using a high-profile, attention-grabbing goal to justify and fund the development of robust, broadly applicable technologies--is a powerful competitive advantage. It allows Colossal to tackle "harder technologies" that have "tremendous value" by operating at the cutting edge of genome engineering, performing "hundreds of edits" with "90% efficiency," far surpassing the typical 30-40% seen elsewhere, especially when working with challenging ancient DNA. This focus on difficult, high-fidelity engineering creates a moat that consumer-facing or simpler technology plays cannot easily replicate.

The Government as a High-Value Customer

Beyond B2B applications, Lamm emphasizes a significant "B2G" (Business-to-Government) strategy, a less visible but potentially more lucrative avenue. Governments, he notes, are already spending "eight and even nine figures" on conservation efforts with limited success due to genetic bottlenecks. Colossal offers a solution: leveraging its advanced technologies to produce "higher genetic diversity" and achieve "outcomes for recovery in country," all while saving governments substantial sums. This positions Colossal not just as a scientific innovator, but as a strategic partner for national initiatives.

An example of this is a "nine-figure deal with the UAE around our bio vault infrastructure," aimed at building a strategy to manage biodiversity. This involves creating a "biodiversity credit score for a country" and predicting extinction impacts, offering a quantifiable return on investment for nations looking to address environmental challenges. This approach moves beyond the abstract appeal of saving species to tangible economic and strategic benefits for sovereign nations. The implication is that by solving complex, large-scale problems for governments, Colossal secures long-term, high-value contracts that dwarf consumer-driven revenue streams.

"We have a data set model then we have a country specific model right so we're working with countries to solve really hard problems using genetic rescue cryopreservation that also are cost savings for the country but pretty massive when it comes to revenue opportunities."

This B2G focus also extends into national security. Lamm acknowledges the dual-use nature of synthetic biology, noting that technologies developed by Colossal are "critical to national security" and are of interest to governments, including intelligence agencies like In-Q-Tel. While explicitly stating they do not work on offensive biotech, Lamm underscores the importance of understanding and leading in these advanced fields. This strategic engagement with government and defense sectors provides a unique revenue stream and a powerful endorsement of the company's technological prowess, creating a competitive advantage that is shielded from typical market fluctuations.

The Long Game: Delayed Payoffs and Competitive Moats

The business model hinges on delayed payoffs and the creation of durable competitive advantages through upfront difficulty. Lamm is candid about the fact that Colossal is "not profitable today," but the path to profitability is "ludicrous." This is because the technologies being developed are inherently complex and require significant upfront investment and expertise. This creates a natural barrier to entry. For instance, working with ancient DNA and ancestral state reconstructions is "significantly harder" than working with fresh samples, leading to higher efficiency and value.

The controversial launch of the dire wolf puppies, while generating academic debate, also served to highlight the company's capabilities and Lamm's willingness to navigate complex public discourse. The controversy, he suggests, was partly due to a "fumbled the ball on the one yard line on launch" regarding communication, but also stemmed from a subset of the academic community arguing over definitions. Lamm's response--to frame Jurassic Park as a story about hubris or dinosaurs, depending on perspective--demonstrates a strategic understanding of narrative control and public engagement. This ability to manage controversy and communicate complex scientific progress, even when met with criticism, is itself a form of competitive advantage, signaling resilience and a clear vision.

"The dire wolf controversy which he talked about sure i mean we can quibble about whether it's a genetically modified gray wolf or not or we can go hey this is really cool and millions of people who didn't care about this dead species now know what it is and know it's not just you know the stark family mascot."

Furthermore, Lamm's emphasis on education and inspiration, while seemingly altruistic, also serves to build a broad base of support and interest in the company's work. By creating "half a billion media impressions" and engaging with educational curricula, Colossal cultivates a future audience and potential talent pool. This long-term vision, extending beyond immediate financial returns, allows the company to pursue ambitious projects that might otherwise be deemed too risky or too slow to yield immediate profits. The investment in conservation projects, which Lamm states outnumber extinction projects, further solidifies this long-term view and builds goodwill, creating a more sustainable and impactful business model.

Key Action Items

• Prioritize Technology Development: Continue to invest heavily in the core genome engineering, computational biology, and AI platforms, recognizing these as the primary drivers of long-term value.
• Expand B2B Licensing: Actively pursue partnerships and licensing agreements for the spun-out technology divisions (Health, plastic degradation, etc.), focusing on high-impact applications.
• Deepen B2G Engagements: Cultivate and expand relationships with governments worldwide, offering solutions for biodiversity management, conservation, and potentially national security applications.
• Strategic Communication: Refine public communication strategies to balance the excitement of de-extinction with clear messaging about the underlying technological advancements and their broader applications.
• Manage Academic Relations: Continue to engage constructively with the scientific community, acknowledging valid critiques while clearly articulating the company's scientific rigor and goals.
• Long-Term Impact Focus: Maintain a commitment to conservation projects, leveraging proprietary technologies to address critical environmental challenges, building both impact and brand reputation.
• Explore Nature Credits: Investigate and develop frameworks for "nature credits" or similar financial instruments that monetize biodiversity and conservation efforts, creating a novel revenue stream.